Headlines about Biohaven Pharmaceutical (NYSE:BHVN) have trended somewhat negative recently, Accern Sentiment reports. Accern scores the sentiment of news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Biohaven Pharmaceutical earned a daily sentiment score of -0.03 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 44.5917991358339 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

These are some of the news articles that may have effected Accern’s scoring:

Shares of Biohaven Pharmaceutical (NYSE:BHVN) traded down $0.40 during trading on Wednesday, reaching $28.53. 487,358 shares of the company were exchanged, compared to its average volume of 453,621. The company has a market cap of $1,040.00 and a PE ratio of -5.22. Biohaven Pharmaceutical has a 52 week low of $17.00 and a 52 week high of $39.51.

A number of analysts have recently weighed in on BHVN shares. Zacks Investment Research raised shares of Biohaven Pharmaceutical from a “hold” rating to a “buy” rating and set a $33.00 target price on the stock in a research report on Friday, March 9th. Canaccord Genuity started coverage on shares of Biohaven Pharmaceutical in a research report on Friday, December 15th. They issued a “buy” rating and a $30.00 target price on the stock. Piper Jaffray Companies set a $48.00 target price on shares of Biohaven Pharmaceutical and gave the stock a “buy” rating in a research report on Monday, December 11th. BidaskClub downgraded shares of Biohaven Pharmaceutical from a “sell” rating to a “strong sell” rating in a research report on Tuesday, November 14th. Finally, Needham & Company LLC reiterated a “buy” rating on shares of Biohaven Pharmaceutical in a research note on Thursday, February 22nd. One research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the stock. Biohaven Pharmaceutical presently has an average rating of “Buy” and an average target price of $38.57.

In other Biohaven Pharmaceutical news, Director Gregory Bailey sold 50,000 shares of the company’s stock in a transaction dated Wednesday, January 31st. The shares were sold at an average price of $33.71, for a total transaction of $1,685,500.00. Following the transaction, the director now owns 2,516,701 shares in the company, valued at approximately $84,837,990.71. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Robert Berman sold 10,000 shares of the company’s stock in a transaction dated Tuesday, December 19th. The shares were sold at an average price of $24.10, for a total transaction of $241,000.00. The disclosure for this sale can be found here. Insiders have sold a total of 837,976 shares of company stock worth $24,007,425 in the last 90 days.

COPYRIGHT VIOLATION NOTICE: This article was first posted by Marea Informative and is the sole property of of Marea Informative. If you are viewing this article on another publication, it was stolen and reposted in violation of US and international copyright law. The original version of this article can be viewed at https://www.mareainformativa.com/2018/03/14/biohaven-pharmaceutical-bhvn-getting-somewhat-negative-news-coverage-report-finds-updated-updated-updated.html.

About Biohaven Pharmaceutical

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.

Insider Buying and Selling by Quarter for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.